IPO
Esperion announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units to eighteen new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.
MGB Biopharma announces the completion of its latest funding round.
Ergomed plc will announce its interim results for the six months ending 30 June 2019 on 25September 2019.
Vivoryon Therapeutics AG announced its financial results for the first six months of 2019 ending June 30.
MyoKardia, Inc., announced its participation in the following upcoming investor conferences:
The first half of the year has been characterized by continued work to develop the company’s innovative projects in two treatment areas, both of which have significant medical needs because the current treatment options are less effective or non-existent.
TLC announced that the management team is scheduled to present at the two upcoming investor conferences
The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014
Investment in life sciences innovation at all-time high, driving demand for new real estate concepts
U.S. biopharmaceutical research and development spending reached a record $179 billion in 2018 and is expected to grow by $34 billion by 2024, an indication that companies are investing now to improve their future pipelines, according to JLL’s eighth annual Life Sciences Outlook.
Resverlogix Corp. announced that its Annual and Special Meeting of Shareholders is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous Learning – Ross Glen Hall, 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at approximately 1:00 pm.
PRESS RELEASES